Actavis Inc has entered into a partnership with QRxPharma to commercialise MoxDuo IR in the US.
Under the terms of a letter of intent, Actavis has exclusive rights to launch and market MoxDuo IR, a patented fixed-dose combination of morphine and oxycodone in a 3:2 ratio.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The product will launch in the US is expected in the third quarter of 2012, with pre-launch preparations set to begin immediately.
Actavis CEO Claudio Albrecht said that the company is serious in its quest to be ahead of the changing generic pharmaceutical industry.
"In the future, there will not be such a clear difference between innovator and generic companies. The lines between the two models are blurring. The generics business as we know it today will be gone within the next ten years," Albrecht said.
This transaction builds on Actavis’s success with the currently marketed Kadian (extended-release morphine sulphate) capsules, and a broad array of generic scheduled narcotics offerings.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
